Engineering these antibodies into bi-specific antibodies coupling to Clec9A, is of special interest in this regard, since thereby dying tumor cell material could be specifically targeted toward the recycling endosomal compartment, thus favoring cross-presentation in BDCA3+ DCs, the alleged human equivalent to mouse CD8α+ DCs (Schreibelt et al., 2012). Here, CD8A is linked to neoplasm.